Which listed company is Opicapone capsules?

Neurocrine Biosciences, a neuroscience-focused biopharmaceutical company, announced in April 2020 that the U.S. Food and Drug Administration (FDA) has approved once-daily oral opicapone 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa for patients with Parkinson's disease experiencing "off" attacks. As the disease progresses, patients taking levodopa/carbidopa may begin to experience "off" times between treatment doses, during which Parkinson's disease motor symptoms such as tremors, slowed movements, and difficulty walking increase. Opicapone also increased the time spent without troublesome dyskinesias "on," the time during which motor symptoms in people with Parkinson's disease are better controlled.